Baloxavir treatment of oseltamivir-resistant influenza A/H1pdm09 in two immunocompromised patients

Nenad Macesic; Jennifer M. Laplante; Justin G. Aaron; Emily A. DiMango; Benjamin A. Miko; Marcus R. Pereira; Ran Reshef; Kirsten St. George

doi:10.1111/tid.13542

Baloxavir treatment of oseltamivir-resistant influenza A/H1pdm09 in two immunocompromised patients

Nenad Macesic, Jennifer M. Laplante, Justin G. Aaron, Emily A. DiMango, Benjamin A. Miko, Marcus R. Pereira, Ran Reshef, Kirsten St. George

Infectious Diseases

Research output: Contribution to journal › Article › Research › peer-review

Abstract

Few treatment options are available for oseltamivir-resistant influenza. It has been proposed that baloxavir can be effective in this setting due to its distinct mechanism of action but clinical experience is lacking for immunocompromised patients. We report two such cases treated with baloxavir after failure of oseltamivir and detection of oseltamivir resistance mutations. Baloxavir/zanamivir combination therapy was effective in one patient, but persistent viral shedding was noted with baloxavir monotherapy in the other patient.

Original language	English
Number of pages	5
Journal	Transplant Infectious Disease
DOIs	https://doi.org/10.1111/tid.13542
Publication status	Accepted/In press - 5 Dec 2020

Keywords

CAR-T cell therapy
H275Y
lung transplant
lymphoma
neuraminidase inhibitor

Access to Document

10.1111/tid.13542

Link to publication in Scopus

Cite this

@article{dcfd1cda903e459f8df415025fa012ea,

title = "Baloxavir treatment of oseltamivir-resistant influenza A/H1pdm09 in two immunocompromised patients",

abstract = "Few treatment options are available for oseltamivir-resistant influenza. It has been proposed that baloxavir can be effective in this setting due to its distinct mechanism of action but clinical experience is lacking for immunocompromised patients. We report two such cases treated with baloxavir after failure of oseltamivir and detection of oseltamivir resistance mutations. Baloxavir/zanamivir combination therapy was effective in one patient, but persistent viral shedding was noted with baloxavir monotherapy in the other patient.",

keywords = "CAR-T cell therapy, H275Y, lung transplant, lymphoma, neuraminidase inhibitor",

author = "Nenad Macesic and Laplante, {Jennifer M.} and Aaron, {Justin G.} and DiMango, {Emily A.} and Miko, {Benjamin A.} and Pereira, {Marcus R.} and Ran Reshef and {St. George}, Kirsten",

year = "2020",

month = dec,

day = "5",

doi = "10.1111/tid.13542",

language = "English",

journal = "Transplant Infectious Disease",

issn = "1398-2273",

publisher = "Wiley-Blackwell",

}

Baloxavir treatment of oseltamivir-resistant influenza A/H1pdm09 in two immunocompromised patients. / Macesic, Nenad; Laplante, Jennifer M.; Aaron, Justin G.; DiMango, Emily A.; Miko, Benjamin A.; Pereira, Marcus R.; Reshef, Ran; St. George, Kirsten.

In: Transplant Infectious Disease, 05.12.2020.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Baloxavir treatment of oseltamivir-resistant influenza A/H1pdm09 in two immunocompromised patients

AU - Macesic, Nenad

AU - Laplante, Jennifer M.

AU - Aaron, Justin G.

AU - DiMango, Emily A.

AU - Miko, Benjamin A.

AU - Pereira, Marcus R.

AU - Reshef, Ran

AU - St. George, Kirsten

PY - 2020/12/5

Y1 - 2020/12/5

N2 - Few treatment options are available for oseltamivir-resistant influenza. It has been proposed that baloxavir can be effective in this setting due to its distinct mechanism of action but clinical experience is lacking for immunocompromised patients. We report two such cases treated with baloxavir after failure of oseltamivir and detection of oseltamivir resistance mutations. Baloxavir/zanamivir combination therapy was effective in one patient, but persistent viral shedding was noted with baloxavir monotherapy in the other patient.

AB - Few treatment options are available for oseltamivir-resistant influenza. It has been proposed that baloxavir can be effective in this setting due to its distinct mechanism of action but clinical experience is lacking for immunocompromised patients. We report two such cases treated with baloxavir after failure of oseltamivir and detection of oseltamivir resistance mutations. Baloxavir/zanamivir combination therapy was effective in one patient, but persistent viral shedding was noted with baloxavir monotherapy in the other patient.

KW - CAR-T cell therapy

KW - H275Y

KW - lung transplant

KW - lymphoma

KW - neuraminidase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85097892812&partnerID=8YFLogxK

U2 - 10.1111/tid.13542

DO - 10.1111/tid.13542

M3 - Article

C2 - 33278052

AN - SCOPUS:85097892812

JO - Transplant Infectious Disease

JF - Transplant Infectious Disease

SN - 1398-2273

ER -